Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01555164 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
A Phase 3 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 442
- Enrollment target
NCT01555164 is a Phase 3 study that has completed, run by Gilead Sciences. The registered enrollment target is 442 participants.
The verdict
NCT01555164, a Phase 3 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 442 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin therapy in addition to diet and exercise.
Interventions
- DRUG Metformin
- BEHAVIORAL Diet
- DRUG Ranolazine
- DRUG Placebo to match ranolazine
- DRUG Placebo to match metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 442 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01555164
The ClinicalTrials.gov registry entry for NCT01555164 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 442 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Metformin is the first listed.
NCT01555164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01555164 about?
NCT01555164 is a clinical study titled "A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone". This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to determine the effect of ranolazine when added to metformin on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are inadequately controlled despite current treatment with stable metformin t...
What is the current status of trial NCT01555164?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 442 participants. The study started on 2012-06. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01555164?
The interventions under investigation include: Metformin (DRUG), Diet (BEHAVIORAL), Ranolazine (DRUG), Placebo to match ranolazine (DRUG), Placebo to match metformin (DRUG).
Who is sponsoring clinical trial NCT01555164?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.